Search…

Lates News

13/05/2025

The drug clinical trial registration and information disclosure platform shows that Pfizer has initiated a Phase I clinical trial of PF-08046054 for solid tumor patients in China. PF-08046054 (SGN-PDL1V) is a PD-L1-targeting ADC acquired by Pfizer from Seagen. This Phase I clinical trial aims to evaluate PF-08046054 as a monotherapy for late-stage solid malignant tumor patients.

Latest

4 m ago

The Hong Kong Securities and Futures Commission and the Ontario Securities Commission of Canada strengthen cooperation in supervising cross-border investment management.

4 m ago

According to a research report released by Shanxi Securities on May 13th, Suntech Power (300274.SZ) was given a buy rating. The main reasons for the rating include: 1) Stable growth in performance in 2024, with significant improvement in operating cash flow in the first quarter of 2024 and 2025; 2) PV inverters: steady growth in business, with basically stable profitability; 3) Energy storage systems: high growth in shipments, demonstrating profitability and resilience. (Daily Economic News)

4 m ago

"Double reduction" of bank financial management under low interest rates: 150 products lower performance compared to baseline, institutions reduce fees to retain customers.

5 m ago

Brent crude oil rose by 1.00% to $65.35 per barrel during the day. WTI crude oil rose by nearly 1.2% to $62.29 per barrel.

5 m ago

Nochang Jianhua: Net profit in the first quarter of 2025 is 17.9676 million yuan.

See all latest